SecSonar.com

Traws Pharma, Inc. (TRAW)

Traws Pharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Traws Pharma, Inc. (TRAW) is a Biotechnology company based in US with a market capitalization of $13.4M. Revenue grew 1134.5% year-over-year and free cash flow was negative at -$20.8M. This page tracks TRAW's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 6 employees · IPO Jul 25, 2013

Valuation

Valuation & price

$1.88 · as of May 17, 2026 · -39.9% vs 52w high

1.7

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$3.01$1.88$0.76Jul 25Dec 25Jul 26Jul 7, 25$1.45Jul 9, 25$1.55Jul 11, 25$1.52Jul 15, 25$1.48Jul 17, 25$1.62Jul 21, 25$1.64Jul 23, 25$1.69Jul 25, 25$1.58Jul 29, 25$1.56Jul 31, 25$1.54Aug 4, 25$1.52Aug 6, 25$1.52Aug 11, 25$1.62Aug 13, 25$1.64Aug 15, 25$1.51Aug 19, 25$1.34Aug 21, 25$1.38Aug 25, 25$1.41Aug 27, 25$1.42Aug 29, 25$1.40Sep 3, 25$1.61Sep 5, 25$1.79Sep 9, 25$1.87Sep 11, 25$1.81Sep 16, 25$2.05Sep 18, 25$2.06Sep 22, 25$1.91Sep 24, 25$1.86Sep 26, 25$1.85Sep 30, 25$1.85Oct 2, 25$1.82Oct 6, 25$2.25Oct 8, 25$2.49Oct 10, 25$3.01Oct 14, 25$2.95Oct 16, 25$2.67Oct 21, 25$2.98Oct 23, 25$2.63Oct 27, 25$2.60Oct 29, 25$2.78Oct 31, 25$2.57Nov 4, 25$2.20Nov 6, 25$2.03Nov 10, 25$1.94Nov 12, 25$2.14Nov 14, 25$2.17Nov 18, 25$2.13Nov 20, 25$2.14Nov 25, 25$2.63Nov 28, 25$2.70Dec 2, 25$2.16Dec 4, 25$2.36Dec 8, 25$2.16Dec 10, 25$2.47Dec 12, 25$2.33Dec 16, 25$2.20Dec 18, 25$1.25Dec 22, 25$1.32Dec 24, 25$1.24Dec 29, 25$1.13Jan 2, 26$1.33Jan 6, 26$1.30Jan 8, 26$1.41Jan 12, 26$1.27Jan 14, 26$1.77Jan 16, 26$2.02Jan 21, 26$2.43Jan 23, 26$2.42Jan 27, 26$2.82Jan 29, 26$2.10Feb 2, 26$2.04Feb 4, 26$1.94Feb 9, 26$1.87Feb 11, 26$1.94Feb 13, 26$1.92Feb 18, 26$1.97Feb 20, 26$1.61Feb 24, 26$1.53Feb 26, 26$1.62Mar 2, 26$1.62Mar 4, 26$1.68Mar 6, 26$1.60Mar 10, 26$1.73Mar 12, 26$2.02Mar 17, 26$2.20Mar 19, 26$2.18Mar 23, 26$2.22Mar 25, 26$2.00Mar 27, 26$1.76Mar 31, 26$1.83Apr 2, 26$1.64Apr 7, 26$1.60Apr 9, 26$1.50Apr 13, 26$1.61Apr 15, 26$1.23Apr 17, 26$1.25Apr 22, 26$1.29Apr 24, 26$1.16Apr 28, 26$1.21Apr 30, 26$1.43May 4, 26$1.51May 6, 26$1.70May 8, 26$2.18May 12, 26$1.68May 14, 26$1.63May 18, 26$1.76May 20, 26$1.62May 22, 26$1.49May 28, 26$1.52Jun 1, 26$1.47Jun 3, 26$1.45Jun 5, 26$1.37Jun 9, 26$1.31Jun 11, 26$1.27Jun 15, 26$0.76Jun 17, 26$0.80Jun 22, 26$0.89Jun 24, 26$0.86Jun 26, 26$0.83Jul 2, 26$0.76
$0.7652-week range$3.13
Loading valuation history…

Fundamentals

Key fundamentals

$13.4M

Market cap

1134.5%

Revenue growth (YoY)

100.0%

Gross margin

-$20.8M

Free cash flow (USD)

-$3.8M

Net debt

Net cash position

429.9%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$5.5MFY 2017$787.0KFY 2018$1.2MFY 2019$2.2MFY 2020$231.0KFY 2021$226.0KFY 2022$226.0KFY 2023$226.0KFY 2024$226.0KFY 2025$2.8M
$5.5M$2.8M

Free cash flow by year

2016 → 2025

FY 2016$-15.8MFY 2017$-23.8MFY 2018$-22.7MFY 2019$-20.9MFY 2020$-23.1MFY 2021$-19.5MFY 2022$-16.3MFY 2023$-17.9MFY 2024$-29.8MFY 2025$-20.8M
-$15.8M-$20.8M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 202494.7%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

1

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: May 15, 2026 (EPS $-0.53)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • FinancingSecurities RegistrationJul 1, 2026Filing
  • 8-K eventRegulatory Submission UpdateJun 22, 2026Filing
  • 8-K eventRegulatory UpdateJun 12, 2026Filing
  • 8-K eventAntiviral Program AnnouncementMay 27, 2026Filing
  • 8-K eventShare OfferingMay 26, 2026Filing
  • 8-K eventQ1 2026 Financial ResultsMay 15, 2026Filing
  • Quarterly report10-Q FiledMay 15, 2026Filing
  • FinancingSecurities RegistrationMay 8, 2026Filing
  • Annual report10-K FiledApr 30, 2026Filing
  • Insider buyInsider Buy $998KORBIMED ADVISORS LLC · 10% Owner · $998.2KApr 28, 2026Filing

Questions

Frequently asked questions

What is Traws Pharma, Inc.'s market cap?

Traws Pharma, Inc. (TRAW) has a market capitalization of $13.4M.

What is TRAW's P/E ratio?

TRAW trades at a price-to-earnings ratio of 1.7, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

When did Traws Pharma, Inc. last report earnings?

TRAW last reported earnings on May 15, 2026; the next date is not yet scheduled.

Are insiders buying TRAW stock?

Yes — SEC Form 4 filings show 1 open-market insider buy and 0 sells at Traws Pharma, Inc. in the last 90 days.

Same arena

Related companies in Biotechnology

GDTC

CytoMed Therapeutics Limited

$13.4M

CYCN

Cyclerion Therapeutics, Inc.

$13.6M

LPCN

Lipocine Inc.

$13.2M

HIND

Vyome Holdings, Inc.

$13M

TAOX

TAO Synergies Inc.

$14M

PSTV

Plus Therapeutics, Inc.

$14.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.